medigraphic.com
Instituto Nacional de Salud Pública

2022, Número 1

<< Anterior Siguiente >>

salud publica mex 2022; 64 (1)


Retrasos del paciente y del tratamiento en mujeres mexicanas con cáncer de mama antes y después del Seguro Popular

Huerta-Gutiérrez R, Murillo-Zamora E, Ángeles-Llerenas A, Ortega-Olvera C, Torres-Mejía G

Idioma: Ingles.
Referencias bibliográficas: 36
Paginas: 87-95
Archivo PDF: 297.93 Kb.


RESUMEN

Objetivo. Evaluar si el Fondo de Protección contra Gastos Catastróficos en Salud (FPGC) se asoció con retrasos en la búsqueda de atención médica e inicio del tratamiento. Material y métodos. Estudio transversal antes y después, que incluyó 266 mujeres con diagnóstico de cáncer de mama (CM) tratadas durante los últimos tres años previos a que los hospitales recibieran el FPGC y 309 mujeres tratadas en los siguientes tres años posteriores a que los hospitales recibieran el fondo. Resultados. El FPGC no se asoció con el retraso en la búsqueda de atención médica ni con el retraso del inicio del tratamiento. Conclusiones. El FPGC no redujo el retraso en la búsqueda de atención médica por CM ni el retraso del inicio del tratamiento.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492

  2. Gómez-Dantés H, Lamadrid-Figueroa H, Cahuana-Hurtado L, Silverman- Retana O, Montero P, González-Robledo MC, et al. The burden of cancer in Mexico, 1990-2013. Salud Pública Méx. 2016;58(2):118-31. https://doi. org/10.21149/spm.v58i2.7780

  3. Justo N, Wilking N, Jonsson B, Luciani S, Cazap E. A Review of Breast Cancer Care and Outcomes in Latin America. Oncologist. 2013;18(3):248- 56. https://doi.org/10.1634/theoncologist.2012-0373

  4. Ángeles-Llerenas A, Torres-Mejía G, Lazcano-Ponce E, Uscanga-Sánchez S, Mainero-Ratchelous F, Hernández-Ávila JE, et al. Effect of care-delivery delay on the survival of Mexican women with breast cancer. Salud Pública Méx. 2016;18(3):237-50. https://doi.org/10.21149/spm.v58i2.7793

  5. Unger-Saldaña K. Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol. 2014;5(3):465- 77. https://doi.org/10.5306/wjco.v5.i3.465

  6. Knaul FM, Nigenda G, Lozano R, Arreola-Ornelas H, Langer A, Frenk J. Breast cancer in Mexico: an urgent priority. Salud Pública Méx. 2009;51(supl 2):335-44. https://doi.org/10.1590/s0036- 36342009000800026

  7. Frenk J, González-Pier E, Gómez-Dantés O, Lezana MA, Knaul FM. Comprehensive reform to improve health system performance in Mexico. Lancet. 2006;368(9546):1524-34. https://doi.org/10.1016/S0140- 6736(06)69564-0

  8. Reynoso-Noverón N, Villarreal-Garza C, Soto-Perez de Celis E, Arce- Salinas C, Matus-Santos J, Ramírez-Ugalde MT, et al. Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular. J Glob Oncol. 2017;3(6):757-64. https://doi.org/10.1200/JGO.2016.007377

  9. Unger-Saldaña K, Ventosa-Santaulària D, Miranda A, Verduzco-Bustos G. Barriers and explanatory mechanisms of delays in the patient and diagnosis intervals of care for breast cancer in Mexico. Oncologist. 2018;23(4):440-53. https://doi.org/10.1634/theoncologist.2017-0431

  10. Tejada-Tayabas LM, Salcedo LA, Monárrez-Espino J. Medical therapeutic itineraries of women with breast cancer diagnosis affiliated to the People’s Health Insurance in San Luis Potosí, central Mexico. Cad Saude Publica. 2015;31(1):60-70. https://doi.org/10.1590/0102-311X00009114

  11. Aapro M, Astier A, Audisio R, Banks I, Bedossa P, Brain E, et al. Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. Eur J Cancer. 2017;82(1):193-202. https://doi.org/10.1016/j.ejca.2017.04.014

  12. Reich MR. Restructuring Health Reform, Mexican Style. Health Syst Reform. 2020;6(1):1-11. https://doi.org/10.1080/23288604.2020.1763114

  13. Pack GT, Gallo JS. The culpability for delay in the treatment of cancer. Am J Cancer. 1938;33(3):443-62. https://doi.org/10.1158/ajc.1938.443

  14. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Ann Oncol. 2008;19(4):614-22. https://doi.org/10.1093/annonc/ mdm481

  15. Kolenikov S, Angeles G. The use of discrete data in principal component analysis for socio-economic status evaluation. Chapel Hill: University of North Carolina, 2005 [cited Feb 25, 2020]. Available from: http://staskolenikov. net/talks/Gustavo-Stas-PCA-generic.pdf

  16. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression: 3rd ed. New Jersey: Wiley Series in Probability and Statistics, 2013 [cited Mar 13, 2020]. Available from: https://onlinelibrary.wiley.com/doi/ book/10.1002/9781118548387

  17. Mohar A, Bargalló E, Ramírez MT, Lara F, Beltrán-Ortega A. Recursos disponibles para el tratamiento del cáncer de mama en México. Salud Pública Méx. 2009;51(suppl 2):s263-9 [cited Mar 13,2020]. Available from: https://www.saludpublica.mx/index.php/spm/article/view/4895

  18. Han X, Zhao J, Ruddy KJ, Lin CC, Sineshaw HM, Jemal A. The impact of dependent coverage expansion under the Affordable Care Act on time to breast cancer treatment among young women. PLoS One. 2018;13(6):e0198771. https://doi.org/10.1371/journal.pone.0198771

  19. Tarazi WW, Bradley CJ, Bear HD, Harless DW, Sabik LM. Impact of Medicaid disenrollment in Tennessee on breast cancer stage at diagnosis and treatment. Cancer. 2017;123(17):3312-9. https://doi.org/10.1002/cncr.30771

  20. Halpern MT, Schrag D. Effects of state-level medicaid policies and patient characteristics on time to breast cancer surgery among medicaid beneficiaries. Breast Cancer Res Treat. 2016;158(3):573-81. https://doi. org/10.1007/s10549-016-3879-8

  21. Piñeros M, Sánchez R, Cendales R, Perry F, Ocampo R. Patient delay among Colombian women with breast cancer. Salud Pública Méx. 2009;51(5):372-80. https://doi.org/10.1590/s0036-36342009000500004

  22. Romanoff A, Constant TH, Johnson KM, Guadiamos MC, Vega AMB, Zunt J, Anderson BO. Association of previous clinical breast examination with reduced delays and earlier-stage breast cancer diagnosis among women in Peru. JAMA Oncol. 2017;3(11):1563-7. https://doi.org/10.1001/ jamaoncol.2017.1023

  23. Unger-Saldaña K, Miranda A, Zarco-Espinosa G, Mainero-Ratchelous F, Bargalló-Rocha E, Lázaro-León JM. Health system delay and its effect on clinical stage of breast cancer: Multicenter study. Cancer. 2015;121(13):2198-206. https://doi.org/10.1002/cncr.29331

  24. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999;353(9159):1119-26. https://doi.org/10.1016/s0140- 6736(99)02143-1

  25. Unger-Saldaña K, Infante-Castañeda C. Delay of medical care for symptomatic breast cancer: a literature review. Salud Publica Mex. 2009;51(supl 2):s270-85. https://doi.org/10.1590/s0036-36342009000800018

  26. Unger-Saldaña K, González-Maya LN, Betancourt AM. Percepciones de personal de salud y experiencias de atención médica de pacientes con cáncer de mama en los principales centros oncológicos públicos disponibles para población no derechohabiente de seguridad social del país respecto a los principales servicios descritos en la Norma Oficial Mexicana 041 para la prevención, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer de mama. Ciudad de México: Fundación Cimab, 2017 [cited Mar 7, 2019]. Available from: https://comesama.org/loginwp/ wp-content/uploads/2020/07/INFORME-FINAL_Encuesta-NOM041.pdf

  27. Mireles-Aguilar T, Tamez-Salazar J, Muñoz-Lozano JF, López-Martínez EA, Romero C, Platas A, et al. Alerta Rosa: Novel alert and navigation breast cancer program in Nuevo Leon, Mexico, for reducing health system interval delays. Oncologist. 2018;23(12):14616. https://doi.org/10.1634/ theoncologist.2018-0226

  28. Odongo J, Makumbi T, Kalungi S, Galukande M. Patient delay factors in women presenting with breast cancer in a low income country. BMC Res Notes. 2015;8(467):1-6. https://doi.org/10.1186/s13104-015-1438-8

  29. Bright K, Barghash M, Donach M, de la Barrera MG, Schneider RJ, Formenti SC. The role of health system factors in delaying final diagnosis and treatment of breast cancer in Mexico City, Mexico. Breast. 2011;20(supl 2):s54-9. https://doi.org/10.1016/j.breast.2011.02.012

  30. Soares-Ferreira NA, Figueiredo-de Carvalho SM, Engrácia-Valenti V, Pinheiro-Bezerra IM, Teixeira-Batista HM, de Abreu LC, et al. Treatment delays among women with breast cancer in a low socio-economic status region in Brazil. BMC Womens Health. 2017;17(1):13. https://doi. org/10.1186/s12905-016-0359-6

  31. Silva A, Molina Y, Hunt B, Markossian T, Saiyed N. Potential impact of the Affordable Care Act’s preventive services provision on breast cancer stage: A preliminary assessment. Cancer Epidemiol. 2017;49(1):108-11. https://doi.org/10.1016/j.canep.2017.05.015

  32. Aizer AA, Falit B, Mendu ML, Chen M-H, Choueiri TK, Hoffman KE, et al. Cancer-specific outcomes among young adults without health insurance. J Clin Oncol. 2014;32(19):2025-30. https://doi.org/10.1200/ JCO.2013.54.2555

  33. Flores-Luna L, Salazar-Martínez E, Duarte-Torres RM, Torres-Mejía G, Alonso-Ruiz P, Lazcano-Ponce E. Prognostic factors related to breast cancer survival. Salud Publica Mex. 2008;50(2):119-25. https://doi.org/10.1590/ s0036-36342008000200005

  34. Unger-Saldaña K, Peláez-Ballestas I, Infante-Castañeda C. Development and validation of a questionnaire to assess delay in treatment for breast cancer. BMC Cancer. 2012;12(1):626. https://doi.org/10.1186/1471-2407- 12-626

  35. Organización Panamericana de la Salud. Metodología de Gestión Productiva de los Servicios de Salud. Introducción y Generalidades. Washington, DC: OPS, 2010 [cited Mar 13, 2020]. Available from: https:// www.paho.org/hq/dmdocuments/2010/MET_GEST_PSS_INTRO_ GENERL_2010SPA.pdf

  36. Dirección General de Epidemiología. Manual metodológico para la evaluación. Ciudad de México: SS, 2019 [cited Mar 13, 2020]. Available from: https://epidemiologia.salud.gob.mx/gobmx/salud/documentos/manuales/ 04_Manual_CAMEXC.pdf




2020     |     www.medigraphic.com